69 -12 (50) 2022 — Nurullaeva Dilnoza Fatullaevna — DEVELOPMENT OF ANEMIA AS AN ADVERSE EVENT OF COMBINED ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

DEVELOPMENT OF ANEMIA AS AN ADVERSE EVENT OF COMBINED ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

Nurullaeva Dilnoza Fatullaevna Bukhara State Medical Institute

Resume

Currently, the standard of care for chronic hepatitis C is antiviral combination therapy (CVTT) using pegylated interferon-alpha (peg-ELISA-α) and ribavirin. However, a serious problem with combination antiviral therapy (CPVT) is the rather frequent development of severe adverse events. The appearance of changes in the peripheral blood jeopardizes the patient’s condition and requires urgent modification of therapy, up to its complete cancellation, which in both cases is the limiting factor in achieving a sustainable virological response.

Key words: CVHC, CVVT, anemia, undesirable effect

First page

396

Last page

399

For citation: Nurullaeva Dilnoza Fatullaevna – DEVELOPMENT OF ANEMIA AS AN ADVERSE EVENT OF COMBINED ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C //New Day in Medicine 12(50)2022 https://clck.ru/33BewL

LIST OF REFERENCES:

1. Sarkisyants N.K. Experience in predicting side effects of treatment of chronic viral hepatitis with peginterferon α-2a with ribavirin / N. K. Sarkisyants, E. G. Grigoryan //Clinical Medicine. – 2013. – No. 5. – P. 46–49.
2. Anemia in patients with chronic hepatitis C receiving combined antiviral therapy, clinical manifestations, pathogenesis features / D.V. Dontsov [et al.] // Modern problems of science and education. – 2014. – No. 3. – S. 1–8.
3. Toyoda H. Pharmacotherapy of chronic hepatitis C virus infection — the IDEAL trial: ‘2b or not 2b (=2a), that is the question’ / H.Toyoda, T.Kumada //Expert Opinion on Pharmacotherapy. – 2009. – Vol. 10, No. 17. – R. 2845-2857.
4. Hung C.H. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response [Electronic resource] /C.H. Hung //Medscape — Mode of access: http://www.medscape.com/ viewarticle/550731. — Date of access: 04.10.16.
5. Khalid M. Side effects of combination of interferon plus ribavirin therapy in patients with chronic hepatitis c; an experience with 400 patients / M. Khalid, M. Noor //Journal of Postgraduate Medical Institute. – 2007. – Vol. 21, No. 3. – P. 187-191.
6. Mukhamedjanova M.H. Anemia in patients with interferences and interpretation of modern therapy //NDM 4(36)2021 P150-152.
7. Mukhamedzhanova M.Kh., Ahmedova N.Sh. Determination of hepsidin in patients with chronic hepatitis associated with chf as a predictor of the severity of hepatocardial syndrome. //Art of Medicine International Medical Scientific Journal 10.5281/zenodo.7361300 Vol 2, Issue 3 P.332-336.